{
    "clinical_study": {
        "@rank": "62035", 
        "acronym": "FAST AR", 
        "arm_group": {
            "arm_group_label": "Advanced Prostate Cancer", 
            "description": "Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice"
        }, 
        "brief_summary": {
            "textblock": "Prospective, observational study to collect and analyze data on patients with advanced\n      hormone dependent prostate cancer treated with Firmagon\u00ae according to routine medical\n      practice in Argentina"
        }, 
        "brief_title": "Effectiveness and Safety of Firmagon\u00ae in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Hormone Dependent Prostate Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual\n             clinical practice\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Contraindications to Firmagon\n\n          -  Patients already on Firmagon therapy"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "200 patients with Advanced Prostate Cancer that receive Firmagon therapy in the context of\n        usual clinical practice"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861236", 
            "org_study_id": "000036"
        }, 
        "intervention": {
            "arm_group_label": "Advanced Prostate Cancer", 
            "description": "Monthly subcutaneous injections", 
            "intervention_name": "Firmagon\u00ae (degarelix)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Androgens"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ingeniero Pablo Nogu\u00e9s", 
                    "country": "Argentina", 
                    "state": "Buenos Aires"
                }, 
                "name": "Hospital de Trauma y Emergencia Dr Federico Abete"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Argentina"
        }, 
        "number_of_groups": "1", 
        "official_title": "Effectiveness and Safety of Firmagon\u00ae in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina", 
        "overall_contact": {
            "email": "DK0-Disclosure@ferring.com", 
            "last_name": "Clinical Development Support"
        }, 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The PFS failure rate will be estimated with time to PFS failure as dependent and adjusting for disease stage at baseline, baseline PSA, baseline testosterone (if available) and baseline serum Alkaline Phosphatase (s-ALP, if available)", 
            "measure": "Progression-free survival (PFS) failure rate (with failure defined as either prostate-specific antigen (PSA) failure, introduction of additional therapy related to prostate cancer, or death)", 
            "safety_issue": "No", 
            "time_frame": "During 3 years treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861236"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "3 Years", 
        "verification_date": "April 2014"
    }
}